Synthetic Plasma Component Development

The contract seeks the development of a synthetic plasma matrix designed to replicate the volume-expanding, colloidal, and biochemical properties of human plasma, with an emphasis on long-term shelf stability and compatibility with other biosynthetic components. This advanced biomaterial must function as a viable substitute in medical scenarios where natural plasma is unavailable or unsuitable, particularly in tactical or field settings where conventional blood products are impractical. The solution must integrate seamlessly with existing biosynthetic systems to enable scalable, reliable use in emergency and combat medicine. The project is issued as a subcontract under the Department of Defense, specifically through the Defense Advanced Research Projects Agency, targeting innovators in biotechnology and synthetic biology. With a North American Industry Classification System code of 325414, it falls within the pharmaceutical and medicinal chemical manufacturing sector. The opportunity was posted on May 1, 2026, and requires proposals to be submitted by May 19, 2026, leaving a narrow window for detailed technical submission. The place of performance and point of contact details are not specified, suggesting flexibility in location but requiring proposers to address compliance with DoD logistics and security standards regardless of operational base.